In 835 patients with severe aortic stenosis in selected anatomies, TAVI with ACURATE neo2 was non-inferior to Evolut for 30-day death, stroke, moderate/severe regurgitation or pacemaker (15.4% vs 30.4%; p<0.001), driven by fewer pacemakers (11.2% vs 26.5%).
RCTn = 835
Feistritzer et al. Comparison of self-expanding transcatheter heart valves for aortic stenosis: the multicentre, randomised, controlled, non-inferiority DOUBLE-CHOICE trial